Confirmed
One controlled phase 3 trial met its main goal, and tolebrutinib is approved for this use.
BTK inhibition (B cells and microglia): slow disability worsening in secondary progressive MS
Trial timeline
Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.
secondary progressive MS · BTK inhibition (B cells and microglia)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 3
- Running now
- 2
- Controlled phase 2/3 trials
- 3
- People in controlled trials
- 3396
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2026 · Placebo-controlled · MSFT-NCT07299019
Phase 3 · 2025 · Placebo-controlled · MSFT-NCT07225504
Phase 3 · 2020 · Placebo-controlled · MSFT-NCT04411641
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 2 → 3
- 2026-10-27First listed as Confirmed
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error